WO1994021309A1 - Polyurethane-coated intravascular prostheses (stents) for the treatment of blood vessel stenosis - Google Patents
Polyurethane-coated intravascular prostheses (stents) for the treatment of blood vessel stenosis Download PDFInfo
- Publication number
- WO1994021309A1 WO1994021309A1 PCT/BE1994/000024 BE9400024W WO9421309A1 WO 1994021309 A1 WO1994021309 A1 WO 1994021309A1 BE 9400024 W BE9400024 W BE 9400024W WO 9421309 A1 WO9421309 A1 WO 9421309A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood vessel
- prostheses
- treatment
- polyurethanes
- coated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
Definitions
- Treatment of blood vessel stenoses by means of a balloon catheter is a popular method. Last year, more than
- One of these new methods consist of placing a metal
- intravascular prothesis at the level of the vessel stenosis.
- This method is very efficient for treating vessel tears which can occur during balloon dilatation.
- the problems with this metallic stents however are that they have proven to be thrombogenic and can cause an acute thrombotic occlusion of the treated blood vessel.
- Amphiphilic polyurethanes were synthesized starting from amphiphilic polyester diols on the basis of ethylene oxide and proylene oxide. By reaction with a diisocyanate and a chain lengthener ( butanediol), a thermoplastic polyurethane is finally obtained. By the appropriate choice of a) the polyesterdiol, especially the proportion of
- polyurethane-coated devices turned out to be very critical. We used certain amounts of gamma radiation which resulted in the formation of further crossbridging of the polymer leading to a more stable and more elastic polymer which is critical during the stent deployment. The resulting polymers turned out to be very stable when inplanted in human or animal tissues or blood vessels. Furthermore they did not provoke any inflammatory reaction.
- stents heparin, hirudin, streptokinase, urokinase, tpa and other anticoagulants
- inflammatory reaction caused by the stent corticosteroids, antimitotics, angiopeptin and other antiinflammatoy drugs.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
A new method to treat blood vessel stenosis using endovascular prostheses which are coated with amphiphilic polyurethanes to which medicines can be coupled. By coating endovascular prosthesis with amphiphilic polyurethanes, we have succeeded in significantly improving the bio- and bloodcompatibility of endovascular prostheses. These amphiphilic polyurethanes have the property, when implanted in human or animal tissue and blood vessels, of remaining stable and seeming not to provoke an inflammatory reaction. Furthermore it is possible to incorporate medicines in these polymers which, after implantation of the polymers, are slowly released at the location of the place of implantation. This system can further reduce the thrombogenicity of the prostheses coated with the polyurethanes and inhibit the rejection against these prostheses.
Description
POLYURETHANE-COATED INTRAVASCULAR PROTHESES (STENTS) FOR THE TREATMENT OF BLOOD VESSEL STENOSES. A new method to treat blood vessel stenoses by means of endovascular protheses which are coated with amphiphylic polyurethanes to which medicines can be coupled.
DESCRIPTION
Treatment of blood vessel stenoses by means of a balloon catheter is a popular method. Last year, more than
6,000 patients with coronary heart disease were treated by this method in our country. The problem with this method is on the one hand the danger that a tear occurs during the blowing up of the balloon whereby the blood vessel c an close and thus cause an acute myocardial infarction, on the other hand it is well documented that this treatment method is accompanied by a frequent restenosis of the treated blood vessel within 6 months of the treatment. To solve this problems, medicines were tested in order to prevent the restenosis and furthermore new devices were developed.
One of these new methods consist of placing a metal
intravascular prothesis (stent) at the level of the vessel stenosis. This method is very efficient for treating vessel tears which can occur during balloon dilatation. The problems with this metallic stents however are that they have proven to be thrombogenic and can cause an acute thrombotic occlusion of the treated blood vessel. On the other hand, it appeared that through the inplantation of a metal stent in a blood vessel, the body can react with an inflammatory
reaction whereby restenosis within the stent can occur.
By covering these endovascular protheses with amphiphylic polyurethanes, we succeeded in significantly limiting both the problem of trombogenecity as well as the problem of reactive hyperproliferatlve response.
Amphiphilic polyurethanes were synthesized starting from amphiphilic polyester diols on the basis of ethylene oxide and proylene oxide. By reaction with a diisocyanate and a chain lengthener ( butanediol), a thermoplastic polyurethane is finally obtained. By the appropriate choice of a) the polyesterdiol, especially the proportion of
ethy leneoxide/propyleneoxide, and b) the molecular weight of the diol, the bio- and blood compatibility can be optimized. Furthermore the kind of sterilisation of
polyurethane-coated devices turned out to be very critical. We used certain amounts of gamma radiation which resulted in the formation of further crossbridging of the polymer leading to a more stable and more elastic polymer which is critical during the stent deployment. The resulting polymers turned out to be very stable when inplanted in human or animal tissues or blood vessels. Furthermore they did not provoke any inflammatory reaction.
Furthermore we were able to load these polyurethanes with medicines, which were released slowly at the polymer
implantation side. These medicines are used to further- decrease the thrombogenecity of the stents (heparin, hirudin, streptokinase, urokinase, tpa and other anticoagulants) and
to inhibit the inflammatory reaction caused by the stent (corticosteroids, antimitotics, angiopeptin and other antiinflammatoy drugs.) Using methylprednisolone loaded polyurethane coated stents we were able to block totally the stent restenosis in a pig coronary model.
APPLICATION POSSIBILITES OF THE SYSTEM
1. Treatment of blood vessel stenosis in humans and animals.
2. Treatment of complications occurring during other
treatment methods of blood vessel stenosis.
3. Treatment of complications occurring during diagnostic procedures.
4. Coating of prosteses, wires, and catheters introduced for medical purposes.
Claims
By coating endovascular protheses with amphiphylic
polyurethanes, we have developed an efficient method to treat blood vessel stenosis. This method proved to considerably limit the thrombogenicity as well as the rejection against endovascular protheses so that this method signifies an important step forward in the treatment of blood vessel stenosis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU61780/94A AU6178094A (en) | 1993-03-24 | 1994-03-24 | Polyurethane-coated intravascular prostheses (stents) for the treatment of blood vessel stenosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE9300285A BE1006819A7 (en) | 1993-03-24 | 1993-03-24 | Polyurethane coated prostheses (stents) FOR THE TREATMENT OF VESSEL CHOKES. |
BE9300285 | 1993-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994021309A1 true WO1994021309A1 (en) | 1994-09-29 |
Family
ID=3886925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BE1994/000024 WO1994021309A1 (en) | 1993-03-24 | 1994-03-24 | Polyurethane-coated intravascular prostheses (stents) for the treatment of blood vessel stenosis |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU6178094A (en) |
BE (1) | BE1006819A7 (en) |
WO (1) | WO1994021309A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997010011A1 (en) * | 1995-09-11 | 1997-03-20 | Schneider (Usa) Inc. | Drug release stent coating process |
US5980972A (en) * | 1996-12-20 | 1999-11-09 | Schneider (Usa) Inc | Method of applying drug-release coatings |
US6099562A (en) * | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US6120536A (en) * | 1995-04-19 | 2000-09-19 | Schneider (Usa) Inc. | Medical devices with long term non-thrombogenic coatings |
WO2002055121A1 (en) * | 2001-01-11 | 2002-07-18 | Biocompatibles Uk Limited | Drug delivery from stents |
US6776796B2 (en) | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
WO2006047378A2 (en) * | 2004-10-21 | 2006-05-04 | Medtronic Vascular, Inc. | Biocompatible and hemocompatible amphiphilic coatings for drug deliver |
US8182527B2 (en) | 2001-05-07 | 2012-05-22 | Cordis Corporation | Heparin barrier coating for controlled drug release |
US8236048B2 (en) | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US8303609B2 (en) | 2000-09-29 | 2012-11-06 | Cordis Corporation | Coated medical devices |
DE102014201889A1 (en) | 2014-02-03 | 2015-08-20 | Aesculap Ag | Medical product for use in the treatment of hernias |
US9308355B2 (en) | 2012-06-01 | 2016-04-12 | Surmodies, Inc. | Apparatus and methods for coating medical devices |
US9827401B2 (en) | 2012-06-01 | 2017-11-28 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
US11628466B2 (en) | 2018-11-29 | 2023-04-18 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
US11819590B2 (en) | 2019-05-13 | 2023-11-21 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4371686A (en) * | 1980-09-12 | 1983-02-01 | Agency Of Industrial Science & Technology Ministry Of International Trade & Industry | Antithrombogenic, highly elastic polyurethane compound |
WO1987004935A1 (en) * | 1986-02-24 | 1987-08-27 | Fischell Robert | An intravascular stent and percutaneous insertion system |
WO1992015286A1 (en) * | 1991-02-27 | 1992-09-17 | Nova Pharmaceutical Corporation | Anti-infective and anti-inflammatory releasing systems for medical devices |
EP0518704A1 (en) * | 1991-06-14 | 1992-12-16 | Scimed Life Systems, Inc. | Temporary stents and method of manufacture |
EP0566245A1 (en) * | 1992-03-19 | 1993-10-20 | Medtronic, Inc. | Intraluminal stent |
-
1993
- 1993-03-24 BE BE9300285A patent/BE1006819A7/en not_active IP Right Cessation
-
1994
- 1994-03-24 WO PCT/BE1994/000024 patent/WO1994021309A1/en active Application Filing
- 1994-03-24 AU AU61780/94A patent/AU6178094A/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4371686A (en) * | 1980-09-12 | 1983-02-01 | Agency Of Industrial Science & Technology Ministry Of International Trade & Industry | Antithrombogenic, highly elastic polyurethane compound |
WO1987004935A1 (en) * | 1986-02-24 | 1987-08-27 | Fischell Robert | An intravascular stent and percutaneous insertion system |
WO1992015286A1 (en) * | 1991-02-27 | 1992-09-17 | Nova Pharmaceutical Corporation | Anti-infective and anti-inflammatory releasing systems for medical devices |
EP0518704A1 (en) * | 1991-06-14 | 1992-12-16 | Scimed Life Systems, Inc. | Temporary stents and method of manufacture |
EP0566245A1 (en) * | 1992-03-19 | 1993-10-20 | Medtronic, Inc. | Intraluminal stent |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6620194B2 (en) | 1995-04-19 | 2003-09-16 | Boston Scientific Scimed, Inc. | Drug coating with topcoat |
US5837313A (en) * | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
US6120536A (en) * | 1995-04-19 | 2000-09-19 | Schneider (Usa) Inc. | Medical devices with long term non-thrombogenic coatings |
US6358556B1 (en) | 1995-04-19 | 2002-03-19 | Boston Scientific Corporation | Drug release stent coating |
AU703805B2 (en) * | 1995-09-11 | 1999-04-01 | Schneider (Usa) Inc. | Drug release stent coating process |
EP1647287A3 (en) * | 1995-09-11 | 2006-04-26 | Boston Scientific Scimed, Inc. | Drug release stent coating process |
EP1647287A2 (en) * | 1995-09-11 | 2006-04-19 | Boston Scientific Scimed, Inc. | Drug release stent coating process |
EP1559439A1 (en) * | 1995-09-11 | 2005-08-03 | Boston Scientific Scimed, Inc. | Drug release stent coating process |
WO1997010011A1 (en) * | 1995-09-11 | 1997-03-20 | Schneider (Usa) Inc. | Drug release stent coating process |
US6284305B1 (en) | 1996-06-13 | 2001-09-04 | Schneider (Usa) Inc. | Drug coating with topcoat |
US6099562A (en) * | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US5980972A (en) * | 1996-12-20 | 1999-11-09 | Schneider (Usa) Inc | Method of applying drug-release coatings |
US6776796B2 (en) | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
US8236048B2 (en) | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US8303609B2 (en) | 2000-09-29 | 2012-11-06 | Cordis Corporation | Coated medical devices |
US8465758B2 (en) | 2001-01-11 | 2013-06-18 | Abbott Laboratories | Drug delivery from stents |
US7713538B2 (en) | 2001-01-11 | 2010-05-11 | Abbott Laboratories | Drug delivery from stents |
US8057814B2 (en) | 2001-01-11 | 2011-11-15 | Abbott Laboratories | Drug delivery from stents |
WO2002055121A1 (en) * | 2001-01-11 | 2002-07-18 | Biocompatibles Uk Limited | Drug delivery from stents |
US8182527B2 (en) | 2001-05-07 | 2012-05-22 | Cordis Corporation | Heparin barrier coating for controlled drug release |
WO2006047378A3 (en) * | 2004-10-21 | 2007-02-15 | Medtronic Vascular Inc | Biocompatible and hemocompatible amphiphilic coatings for drug deliver |
WO2006047378A2 (en) * | 2004-10-21 | 2006-05-04 | Medtronic Vascular, Inc. | Biocompatible and hemocompatible amphiphilic coatings for drug deliver |
US9827401B2 (en) | 2012-06-01 | 2017-11-28 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
US9308355B2 (en) | 2012-06-01 | 2016-04-12 | Surmodies, Inc. | Apparatus and methods for coating medical devices |
US9623215B2 (en) | 2012-06-01 | 2017-04-18 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
US10099041B2 (en) | 2012-06-01 | 2018-10-16 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
US10507309B2 (en) | 2012-06-01 | 2019-12-17 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
DE102014201889A1 (en) | 2014-02-03 | 2015-08-20 | Aesculap Ag | Medical product for use in the treatment of hernias |
US11628466B2 (en) | 2018-11-29 | 2023-04-18 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
US11819590B2 (en) | 2019-05-13 | 2023-11-21 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
Also Published As
Publication number | Publication date |
---|---|
BE1006819A7 (en) | 1994-12-13 |
AU6178094A (en) | 1994-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Peng et al. | Role of polymers in improving the results of stenting in coronary arteries | |
US20050049691A1 (en) | Polymeric reconstrainable, repositionable, detachable, percutaneous endovascular stentgraft | |
US5800507A (en) | Intraluminal stent | |
US6309380B1 (en) | Drug delivery via conformal film | |
WO1994021309A1 (en) | Polyurethane-coated intravascular prostheses (stents) for the treatment of blood vessel stenosis | |
US6203536B1 (en) | Medical device for delivering a therapeutic substance and method therefor | |
CA2579076C (en) | Stents | |
Liermann et al. | The Strecker stent: indications and results in iliac and femoropopliteal arteries | |
Ozaki et al. | New stent technologies | |
EP0959952A1 (en) | AN IMPLANTABLE DEVICE FOR DELIVERING LOCALIZED RADIATION $i(IN VIVO) AND METHOD FOR MAKING THE SAME | |
BE1008260A6 (en) | Amphiphile polyurethane charged with medicine which is coated onto vascularstents for the treatment of blood vessel constriction | |
EP1363560A2 (en) | Apparatus and method for maintaining flow through a vessel or duct | |
Ellis et al. | Intracoronary stents: will they fulfill their promise as an adjunct to angioplasty? | |
Violaris et al. | Endovascular stents: a ‘break through technology’, future challenges | |
Sangeetha et al. | Degradable metallic biomaterials for cardiovascular applications | |
O'LAUGHLIN | Balloon‐expandable stenting in pediatric cardiology | |
SIGWART | Ten years of stenting: what next? | |
EP1847279B1 (en) | Drug delivery via conformal film | |
Fajadet et al. | Coronary Stenting with the Palmaz-Schatz Stent: The Clinic Pasteur Interventional Cardiology Unit Experience | |
BE1006816A7 (en) | Polyphosphazene-coated prosthesis (stents) for the treatment of blood vessel constriction | |
Triller et al. | Vascular endoprostheses (Stents) in the treatment of femoropopliteal vascular occlusions | |
Hayenga et al. | Perspectives on the Mechanics of Biomaterials in Medical Devices | |
Sukumaran et al. | K. Sangeetha1, AV Jisha Kumari2, Jayachandran Venkatesan3 | |
Lau | PREVENTION OF RESTENOSIS | |
Unverdorben et al. | Stents in the second decade: meshes maturate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BG BR CA CN CZ HU JP NZ PL RO RU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |